Adaptive Biotechnologies Corp. (ADPT)
15.42
-0.32
(-2.03%)
USD |
NASDAQ |
Dec 11, 16:00
15.50
+0.08
(+0.52%)
Pre-Market: 08:36
Adaptive Biotechnologies Research and Development Expense (Quarterly): 20.92M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Akero Therapeutics, Inc. | 78.88M |
| Ionis Pharmaceuticals, Inc. | 217.13M |
| Regeneron Pharmaceuticals, Inc. | 1.338B |
| Vertex Pharmaceuticals, Inc. | 977.70M |
| Ultragenyx Pharmaceutical, Inc. | 207.61M |